Tavapadon in Parkinson's disease

Tavapadon is an oral, once-daily, highly selective dopamine D1/D5 receptor partial agonist evaluated for the treatment of Parkinson's disease (1, 2):

• unlike traditional non-ergot dopamine agonists (for example pramipexole, ropinirole) which preferentially target D2/D3 receptors, tavapadon selectively activates D1/D5 receptors to stimulate the direct motor pathway while minimizing motor fluctuations and D2-mediated adverse effects (1, 2)
• phase 3 evidence from the TEMPO trial program demonstrates efficacy both as monotherapy in early Parkinson's disease and as adjunctive therapy to levodopa in patients with motor fluctuations (1, 3)

Mechanism of Action

• acts as a partial agonist at D1 and D5 dopamine receptors with high functional selectivity (1)
• targeted activation of direct pathway striatal neurons aims to restore motor control while avoiding overstimulation, potentially offering an improved therapeutic window with reduced dyskinesia and somnolence (1)

Summary of Phase 3 TEMPO Clinical Trials

TEMPO-1 (Early Parkinson's Disease Monotherapy - Fixed Dose)

• evaluated fixed doses of tavapadon (5 mg or 15 mg daily) versus placebo over 26 weeks in patients with early Parkinson's disease (3)
• primary endpoint achieved: significant improvement in combined MDS-UPDRS Part II (activities of daily living) and Part III (motor exam) scores at week 26 compared with placebo (3)
• both 5 mg and 15 mg cohorts demonstrated clinically meaningful motor improvements (-11.4 and -12.1 points vs placebo, p < 0.001) (3)

TEMPO-2 (Early Parkinson's Disease Monotherapy - Flexible Dose)

• evaluated flexible dosing of tavapadon (5–15 mg daily) versus placebo over 26 weeks in early Parkinson's disease (2, 3)
• significantly improved combined MDS-UPDRS Part II and III scores compared with placebo (-10.3 vs -1.2 points, p < 0.0001) (2, 3)
• significantly improved MDS-UPDRS Part II (daily living activities) scores alone (-1.5 vs 0.0, p = 0.0007) (2)

TEMPO-3 (Adjunctive Therapy with Levodopa in Motor Fluctuations)

• evaluated tavapadon (5–15 mg daily) as an add-on therapy to levodopa over 27 weeks in patients experiencing motor "off" times (1)
• primary endpoint achieved: statistically significant increase in total daily "ON" time without troublesome dyskinesia compared with placebo (+1.1 hours improvement over placebo, p < 0.001) (1)
• resulted in a concordant reduction in daily "OFF" time of approximately 1 hour compared with placebo (-0.94 hours, p < 0.001) (1)

TEMPO-4 (Long-Term Open-Label Extension)

• evaluated durability and safety out to 85 weeks across monotherapy and adjunctive trial cohorts (1, 2)
• levodopa sparing effect: among patients receiving tavapadon monotherapy for 85 weeks, 94% (257/273) did not require initiation of levodopa (2)
• dose stability: among patients receiving adjunctive tavapadon plus levodopa for 85 weeks, 93% (96/103) did not require an increase in their baseline levodopa dose (2)

Adverse Effects and Safety Profile

• monotherapy adverse events: most common included nausea (25.4%), headache (16.7%), dizziness (12.7%), fatigue, vomiting, dry mouth, and anxiety (3)
• adjunctive adverse events: most common included nausea, dyskinesia, dizziness, headache, hallucinations, and orthostatic hypotension (1)
• class-related precautions: clinicians must monitor for orthostatic hypotension, dyskinesia risk, somnolence/sudden sleep onset, and impulse control disorders (gambling, hypersexuality, compulsive buying) (1, 2)

Reference:

1. Fernandez HH, Isaacson SH, Hauser RA, et al. Tavapadon as adjunctive treatment for Parkinson disease: the TEMPO-3 randomized clinical trial. JAMA Neurol. 2026;83(5):442-451. doi:10.1001/jamaneurol.2026.0577
2. AbbVie Inc. U.S. FDA approves AbbVie's JUVMO (tavapadon) for Parkinson's disease. Published Sep 2026.
3. Pahwa R, Moro E, Espay AJ, et al. Fixed-dose tavapadon for early Parkinson disease: a randomized clinical trial. JAMA Neurol. 2026;83(5):452-460